DORA: A Doravirine-based First-line Antiretroviral Therapy for Women of Reproductive Potential Living With HIV
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
This is a pilot study investigating the safety of Doravirine (DOR) in combination with
Lamivudine (3TC) and Tenofovir Disoproxil Fumarate (TDF) administered over 48 weeks in women
of reproductive potential living with HIV-1 switched from Efavirenz or Dolutegravir-based
antiretroviral therapy on metabolic and neuropsychiatric outcomes.
Phase:
Phase 3
Details
Lead Sponsor:
Professor Francois Venter Willem Daniel Francois Venter